Panacea Biotec Limited
PANACEABIO · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹490.77. Low-confidence estimate — limited data.
Piotroski F-score 2/9 — quality of earnings & balance sheet.
Investability checklist
- –ROE above 15%
- ✓Low debt (D/E < 0.5)0.03x
- ✕Positive free cash flow
- ✕Revenue growth > 10%1%
- ✕Earnings growing-12%
- ✕Net margin ≥ 10%-1.3%
- –Current ratio > 1.5
- ✓Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 6.21
- ✕Piotroski ≥ 72/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 6.21.
Weaknesses
- •Weak Piotroski score (2/9).
Threats
- •Earnings contracting year on year.
About Panacea Biotec Limited
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthop
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.